Article Text

Download PDFPDF

O24 Flare assessments in patients with active systemic lupus erythematosus (SLE) treated with anifrolumab in 2 phase 3 trials
  1. Richard Furie1,
  2. Eric F Morand2,
  3. Anca Askanase3,
  4. Ed Vital4,5,
  5. Rubana N Kalyani6,
  6. Gabriel Abreu7,
  7. Lilia Pineda6 and
  8. Raj Tummala6
  1. 1Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, USA
  2. 2Monash University, Melbourne, VIC, Australia
  3. 3Columbia University College of Physicians and Surgeons, New York, NY, USA
  4. 4University of Leeds, Leeds, UK
  5. 5NIHR Leeds Biomedical Research Centre at Leeds Teaching Hospitals NHS Trust, Leeds, UK
  6. 6AstraZeneca, Gaithersburg, MD, USA
  7. 7AstraZeneca, Gothenburg, Sweden


Background Anifrolumab treatment improved BICLA response rates in patients with SLE in the phase 3 TULIP-2 and TULIP-1 trials (Morand et al, 2020; Furie et al, 2019). In addition, annualized flare rates were lower with anifrolumab vs placebo. TULIP-2 and TULIP-1 data were analyzed to assess effects of anifrolumab on the number of flares and time to first flare during 52 weeks of treatment.

Methods The randomized, double-blind, placebo-controlled TULIP-2 and TULIP-1 trials evaluated efficacy and safety of intravenous anifrolumab (300 mg Q4W) over 52 weeks in patients with moderate to severe SLE despite standard-of-care treatment. Flares were defined as ≥1 new BILAG-2004 A or ≥2 new (worsening) BILAG-2004 B domain scores compared with the prior month’s visit. Number of flares, time to first flare, and annualized flare rate were assessed.

Results In TULIP-2 (anifrolumab, n=180; placebo, n=182) and TULIP-1 (anifrolumab, n=180; placebo, n=184), fewer anifrolumab-treated patients experienced ≥1 flare (TULIP-2: 31.1%, n=56; TULIP-1: 36.1%, n=65) vs placebo-treated patients (TULIP-2: 42.3%, n=77; TULIP-1: 43.5%, n=80). Results favoring anifrolumab were observed in time to first flare (TULIP-2: hazard ratio [HR]=0.65, 95% confidence interval [CI] 0.46–0.91; TULIP-1: HR=0.76, 95% CI 0.55–1.06; figure 1) and annualized flare rates (TULIP-2: adjusted rate ratio=0.67, 95% CI 0.48–0.94; TULIP-1: rate ratio=0.83, 95% CI 0.60–1.14).

Abstract O24 Figure 1

Time to first flare in TULIP-2 and TULIP-1

Conclusions Across 2 phase 3 trials, we observed reduced total number of flares and annualized flare rates, as well as prolongation of time to first flare with anifrolumab treatment vs placebo. These results support the potential of anifrolumab to reduce disease activity and reduce flares, benefiting patients with SLE.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.